.jpeg)
2026-09-20 03:11:47
Fayuvi is a one-time AAV9 intravenous gene therapy that delivers functional SGSH for pediatric MPS IIIA (Sanfilippo A) with preserved neurodevelopment. It lowers CSF heparan sulfate and slows cognitive decline; monitor transaminases, blood counts, fever, TMA, amylase, and long-term integration/oncology risk.
2026-09-20 03:07:09
Ramosetron Hydrochloride orally disintegrating tablets are selective 5-HT3 receptor antagonists that act on gastrointestinal neural signaling pathways. Approved indications vary by region; in Japan, ramosetron is approved for adults with diarrhea-predominant irritable bowel syndrome, but it is not approved for this indication in every country or region.
2026-09-17 03:06:52
Pixclara is Telix’s F-18 amino-acid PET agent for adults and children aged 1 month and older, used with PET to help differentiate recurrent or progressive glioma from treatment-related brain changes. Interpret alongside MRI, history, and clinical findings rather than as stand-alone proof.
2026-09-17 02:41:20
Bexlutry is Curium’s lutetium-177 octreotate radioligand for adults with somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors. Standard regimen is 7.4GBq IV every 8 weeks for 4 cycles with amino-acid renal protection; monitor marrow, kidney, liver, and carcinoid crisis.
2026-09-15 07:32:36
Hibsago (bepirovirsen), an GSK/Ionis antisense oligonucleotide, was approved in Japan for adult chronic hepatitis B functional cure. This page covers its ASO mechanism, 6-month subcutaneous regimen, pooled B-Well 1/2 functional cure rates, and safety notes on injection-site reactions and transaminases.
2026-09-15 07:24:01
In September 2026, the FDA approved Scholar Rock’s Isembyld (apitegromab-mstn) for Spinal Muscular Atrophy (SMA). As the first therapy targeting skeletal muscle, it offers a novel combination approach alongside SMN2-directed therapies for patients aged 2 and older.
2026-09-08 05:39:33
Mirogabalin is used for neuropathic pain, but its analgesic effect is not immediate. This article explains dose titration, factors affecting onset, and the need for continuous observation.
2026-09-07 04:57:52
FDA approved Zanvastro intrathecal injection in September 2026 as the first disease-modifying drug for Alexander disease. This article covers its ASO mechanism, all-age indication, clinical trial efficacy, and safety guidelines.
2026-08-31 02:30:28
On August 27, 2026, the FDA approved once-daily oral brepocitinib 30 mg for adults with dermatomyositis — the first targeted and first oral therapy ever approved for the disease.
2026-08-28 06:51:52
In August 2026, the U.S. FDA granted accelerated approval to daraxonrasib (Rasonque), an oral RAS(ON) inhibitor developed by Revolution Medicines. The drug significantly improves survival in metastatic pancreatic cancer, reshaping the treatment landscape.
2026-08-27 05:38:45
In August 2026, the FDA approved zanidatamab (Ziihera) in combination with tislelizumab and chemotherapy for HER2-positive advanced gastroesophageal adenocarcinoma, achieving a median OS of 26.4 months. This article details the clinical data, indications, safety warnings, and dosing guidelines.
2026-08-24 07:36:03
Two neurokinin receptor antagonists—fezolinetant and elinzanetant—have been approved as non-hormonal therapies for menopausal vasomotor symptoms. Data from the 2026 NIRVANA trial further confirm elinzanetant's efficacy in improving menopause-related sleep disturbances.
